Search Bar & Filters
Found 191 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary antitumor activity of paxalisib combined with temozolomide in patients with high-grade malignant brain tumors, including glioblastoma. This Phase 1b and Phase 2 study is part of the 5G-PEARL trial, which uses biomarker-guided approaches to treat tumors with specific genetic changes such as PI3K mutations or PTEN loss. The study aims to test these treatments in molecularly defined patient groups to better understand their effects. The study includes two parts Phase 1b focuses on safety and early activity, while Phase 2 assesses effectiveness further. In Phase 1b, patients receive paxalisib starting at 45 mg once daily, with a possible increase to 60 mg per day in Cycle 2. Temozolomide is taken orally once daily on days 1 to 5 of each 28-day cycle, starting at 150 mgm2 with potential dose increase to 200 mgm2 from Cycle 3 if tolerated. The trial enrolls patients into two biomarker arms based on tumor genetics, with adaptive decision points to guide study progress. Participants will have assessments including safety monitoring and genetic biomarker analysis over up to two years, depending on the phase. Researchers measure treatment-emergent adverse events and antitumor activity as primary outcomes. Quality of life and additional biomarker responses are also evaluated. Patients will be monitored regularly through clinical visits and tests to track treatment effects and side effects throughout the study duration.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary antitumour activity of two investigational drugs, avutometinib and defactinib, in patients with high grade malignant brain tumours, including glioblastoma GBM. This Phase 12 clinical trial uses biomarker-guided approaches to target specific molecular subtypes of brain tumours. The study is part of the Minderoo 5G platform and includes patients with relapsed or frontline minimal residual disease MRD settings. In Phase 1b, patients with relapsed GBM will receive oral avutometinib at a dose of 3.2 mg twice weekly and defactinib at 200 mg twice daily after meals, aiming for a total weekly dose of 6.4 mg and daily dose of 400 mg respectively. Phase 2 will test the antitumour activity of these drugs given at the recommended dose, either as a doublet or combined with temozolomide, depending on earlier results. Treatment will be given in molecularly defined biomarker arms, with decisions guided by safety and efficacy data. Participants will undergo assessments for safety, tolerability, and tumour response over 9 to 12 months. Molecular profiling will help identify response markers, and quality of life will be monitored during Phase 2. Patients must consent to genomic testing and will be followed regularly with clinical evaluations. The study includes rigorous monitoring for side effects and disease progression, with a total participation duration aligned with treatment phases and follow-up.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.
Actively Recruiting
Researchers are evaluating the safety, optimal dose, and effectiveness of a combination treatment involving BNT323 trastuzumab pamirtecan and BNT327 pumitamig in people with advanced breast cancer. This includes patients with hormone receptor-positive or negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III, multi-site, open-label trial designed to find the best dose and assess the treatments effects in these groups. The study has two parts. Part 1 involves dose escalation where participants with chemotherapy-pretreated advanced breast cancer receive various dose levels of BNT323 plus BNT327 to determine the recommended Phase 2 dose. Part 2 includes dose optimization and exploratory groups, beginning after Part 1s completion. In Part 2 Cohort 1, participants are randomized into four arms to receive either the combination at the recommended dose, the combination at another dose, BNT323 alone, or BNT327 alone. Other cohorts receive the recommended dose without randomization. Participants will undergo treatment cycles with intravenous infusions of the study drugs and be monitored for safety, side effects, and tumor response for up to 36 months. Assessments include tracking dose-limiting toxicities, adverse events, tumor scans, and response rates. Safety monitoring continues up to 90 days after the last dose. The study aims to provide detailed information on the best dose, safety, and potential benefits of these treatments for advanced breast cancer.
Actively Recruiting
Researchers are evaluating new treatment combinations involving BNT314 and pumitamig alongside chemotherapy in people with metastatic colorectal cancer mCRC that is microsatellite stable or mismatch repair proficient. This study includes three parts Part A focuses on safety and dose escalation of BNT314 with pumitamig Part B assesses safety and dosing of BNT314 combined with pumitamig and standard chemotherapy in treatment-nafve or previously treated patients Part C tests effectiveness of these combinations compared to usual chemotherapy treatments. The study aims to see if these treatments can shrink tumors or slow cancer growth. Participants receive intravenous infusions of BNT314 and pumitamig, along with standard of care SoC chemotherapy, in various dose levels and combinations depending on the study part. Part A evaluates up to five dose levels of BNT314 and one or two doses of pumitamig. Part B uses optimized doses of BNT314 with pumitamig and one of two chemotherapy regimens. Part C compares the recommended BNT314 and pumitamig doses plus chemotherapy against other treatment combinations, including bevacizumab with chemotherapy or pumitamig with chemotherapy. Treatment continues until disease progression, intolerance, withdrawal, or study end. Participants undergo eligibility screening, then receive treatment for an average of 6 to 10 months. They are regularly monitored for safety and treatment effects, including tumor response and side effects, with assessments extending up to 57 months after starting treatment. After treatment ends, participants enter safety follow-up and long-term survival monitoring to track any lasting effects and overall outcomes. Randomization is used in Parts B and C to assign treatments by chance.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.
Actively Recruiting
Researchers are investigating a combination therapy of BNT326 and pumitamig for adults with advanced or metastatic non-small cell lung cancer NSCLC that has either relapsed, progressed, or is treatment-nafve. The study includes multiple parts to find the best dose levels, assess safety and tolerability, and evaluate how well the therapy works to shrink tumors in this patient population. The trial is open-label and conducted across multiple sites, focusing on participants with confirmed advanced NSCLC where no curative treatment is available. The study consists of three parts Part 1 focuses on finding safe dose combinations of BNT326 with pumitamig Part 2a expands the dose evaluation to examine preliminary effectiveness and safety and Part 2b randomizes participants to optimize dosing and assess the contribution of each therapy component. Participants with prior treatment and those who are treatment-nafve are enrolled in different cohorts. Treatment is administered via intravenous infusion, and dose levels for Part 2b are determined based on earlier results. Participants undergo a screening period before starting treatment, which can continue for up to 24 months or until disease progression or unacceptable side effects occur. Follow-up periods monitor safety, efficacy, and long-term survival, with total involvement expected to last about 36 months unless ongoing benefit warrants extended treatment. Researchers evaluate dose-limiting toxicities, adverse events, tumor response rates, progression-free survival, and pharmacokinetics to understand treatment effects and participant outcomes.
Actively Recruiting
Researchers are evaluating the safety and potential benefits of the investigational drug BNT329 in adults with advanced solid tumors known to express the tumor marker CA19-9. This multi-part phase IIIa trial aims to find the best dose of BNT329 by monitoring side effects and measuring how well participants respond to treatment, including how long their tumors remain stable. The study also investigates how BNT329 moves through and affects the body. The study includes up to four parts Parts A and B focus on dose escalation to assess safety and tolerability in participants with various advanced cancers expressing CA19-9, such as pancreatic, bile duct, bladder, colorectal, gastric, endometrial, and ovarian cancers. Part C may be opened if safety or efficacy concerns arise and involves pre-dosing with a CA19-9 targeting monoclonal antibody. Part D is a dose optimization and proof-of-concept phase enrolling participants with pancreatic cancer who have progressed after prior therapies. Treatments involve intravenous infusions of BNT329 administered every 2 or 3 weeks, with some participants randomized to different dose levels. Participants will undergo a screening period followed by up to 2 years of treatment, including an end-of-treatment visit and two safety follow-up visits. After treatment, participants will enter a survival follow-up phase lasting until death, withdrawal, or study end. Throughout the study, researchers will assess side effects, tumor response, drug levels, and survival outcomes using clinical evaluations and laboratory tests to monitor safety and effectiveness.
Actively Recruiting
Researchers are investigating BAY 3547926, a new drug designed to treat advanced hepatocellular carcinoma HCC, a type of liver cancer that shows a specific protein called Glypican 3 GPC3. This first-in-human study aims to evaluate the safety, how well the drug works, and the best dose for patients with advanced HCC. The drug works by delivering a radioactive agent to cancer cells to damage and kill them with minimal harm to nearby healthy tissues. Participants will join one of four parts of the study. In Part 1, different doses of BAY 3547926 alone will be tested to find the safest and most effective dose. Then, in Part 2, a larger group will receive the chosen dose alone, while Parts 3 and 4 will explore BAY 3547926 combined with other treatments. The study uses an open-label design without randomization, and the drug is given as an antibody conjugate labeled with actinium-225. Throughout the study, participants will have health check-ups, imaging scans, and blood and urine sample collections. They will also be asked about their health status and symptoms. Researchers will monitor side effects, drug absorption and distribution, and tumor response using imaging criteria. The study tracks outcomes for up to 60 months after the first drug administration to evaluate safety, anti-tumor activity, and pharmacokinetics.
1-10 of 191
1